|
|
 |
| |
|
Home > Drug Companies > United Therapeutics
| |
Pharmaceutical Courses |
|
Pharmacy Technician
Allied College
Arnold, MO |
Pharmacy Technician
Allied College
Saint Ann, MO |
Pharmacy Technician
Cambridge College
Portland, OR |
Pharmacy Technician
Cambridge College
Seattle, WA |
Pharmacy Technician
High Tech Institute
Irving, TX |
Pharmacy Technician
High Tech Institute
Atlanta, GA |
Pharmacy Technician
High Tech Institute
Memphis, TN |
Pharmacy Technician
High Tech Institute
Minneapolis, MN |
Pharmacy Technician
High Tech Institute
Orlando, FL |
Pharmacy Technician
High Tech Institute
Sacramento, CA |
Pharmacy Technician
The Bryman School
Phoenix, AZ |
|
United Therapeutics
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine. United Therapeutics Corporation is incorporated in Delaware and is listed on the NASDAQ stock market.
At United Therapeutics, they find tremendous inspiration for their work and view their products as being new beginnings for patients and doctors, with quality of life as their utmost therapeutic goal. The theme of United Therapeutics is Medicines for Life because all of their therapeutics addresses life-threatening illnesses.
Much of United Therapeutics' resources are focused on cardiovascular health, including developing analogs of the endogenous hormone prostacyclin for the treatment of pulmonary arterial hypertension and critical limb ischemia and a variety of telemedicine services for patients with an array of possible cardiac arrhythmias.
United Therapeutics' second principal focus is oncology and the company is undertaking the largest ever pivotal trial of a potential medicine for preventing the recurrence of ovarian cancer. This medicine is part of a family of similar immunotherapeutic monoclonal antibody therapies licensed to United Therapeutics which are designed to combat prostate, breast, lung, pancreatic, colorectal and multiple myeloma cancers.
United Therapeutics's third focus is in the field of infectious disease, where the company is targeting hepatitis C and other diseases with unique glycobiology compounds. While this work is at an early stage, it holds immense promise. The diseases being targeted afflict over a billion people worldwide, and the compounds are part of an entire new class of pharmacological agents.
They strive for balance within and across their therapeutic areas. Their cardiovascular drug development strategy is balanced with a commercialized use pulmonary arterial hypertension, as well as novel uses and new routes of administration. And their overall company strategy is balanced among mature programs cardiovascular, pivotal development oncology, and early-stage pipeline activities infectious disease.
The company's mission is carried out using corporate partners for product sales and academic centers for research whenever feasible, complemented by in-house commercialization professionals and their commitment to providing doctors and patients with accurate information and ongoing research related to their products. This strategy streamlines company overhead and enables company employees to concentrate on clinical trials, regulatory approvals and business development. United Therapeutics generally retains all rights to the products it develops.
Back to Drug Companies
|
|
|
|
|
|
|
|